Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Virtual Event

27 may 2020 10:45 a.m. - 29 may 2020 3:30 p.m.

(US Eastern Standard Time)

Fort Washington, PA 19034

DIA/FDA Biostatistics Industry and Regulator Forum

Session 2: Statistical, Regulatory, and Operational Considerations for the Use of Digital Health Technologies and Endpoints in Clinical Trials

Session Chair(s)

Jonathan  Haddad, MPH

Jonathan Haddad, MPH

HIV Disease Area Head, Clinical Statistics

GlaxoSmithKline, United States

Scott  Komo, DrPH

Scott Komo, DrPH

Lead Mathematical Statistician, Office of Translational Sciences, CDER

FDA, United States

This session will briefly review the digital health technology landscape as it pertains to clinical trials. Examples of where digital health technology data/endpoints are incorporated in clinical trials and the statistical, regulatory, and operational considerations will be presented. Representatives from Working Groups in this space will discuss key challenges and next steps to realize greater integration of digital data (the future).

Learning Objective :

At the conclusion of this session, participants should be able to:

  • Understand the potential uses of digital health technologies in drug development
  • Gain awareness of key statistical and regulatory challenges with developing and analyzing digital health technology endpoint in clinical trials
  • Gain of awareness of key logistical and operational challenges in using digital health technologies in clinical trials

Speaker(s)

Andrew  Potter, PhD

Missing Data and Other Statistical Considerations for Wearable Activity Monitors in Clinical Trials

Andrew Potter, PhD

FDA, United States

Mathematical Statistician, OB, OTS, CDER

Luis  Garcia-Gancedo, PhD

Digital Health Technology Tools in Clinical Trials: Challenges and Opportunities

Luis Garcia-Gancedo, PhD

GSK, United Kingdom

Director, Digital Biomarkers

Tyler  Reynolds

Considerations for Operationalizing Digital Health Technologies

Tyler Reynolds

PA Consulting, United States

Digital Health Consultant

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.